As a proud Yale University spin-out, we’re pleased to once again participate in Yale Ventures Yale Innovation Summit! Our co-founders John Krystal and Dina Burkitbayeva will take part in this Thursday’s biotech panel, Exploring the Psychedelic Renaissance. #YaleInnovation24 #Biotech
Freedom Biosciences
Biotechnology Research
Next generation psychedelic therapeutics biotech platform
About us
Freedom Biosciences is a clinical-stage biotechnology platform developing next-generation neuropsychiatric therapeutics. Through its discovery platform, Freedom Biosciences has identified the most efficacious combinations of chemicals to advance the safety and therapeutic profiles of existing therapeutics. With programs with clinical data and multiple exploratory programs, Freedom Biosciences has a diverse portfolio of assets that are positioned to significantly change the way we treat mental health indications. Freedom Biosciences is co-founded by Dr. John Krystal and Dina Burkitbayeva. Dr. John Krystal is the Chair of the Department of Psychiatry at Yale University and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. Dina Burkitbayeva is a co-founder of PsyMed Ventures.
- Website
-
www.freedombio.co
External link for Freedom Biosciences
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2021
Employees at Freedom Biosciences
-
David Hough
Neuroscience pharmaceutical research physician and consultant
-
Gurdane Singh Bhutani
Gurdane Singh Bhutani is an Influencer Investing in Environment Health at MBX Capital
-
Hunter R. Bouchard
Principal at Burton Capital Group; Co-Founder at Freedom Biosciences
-
Aakash Saraiya
Emergency Medicine Physician at Newark Beth
Updates
-
We're very excited to announce the FDA Approval of IND Application of our FREE001 Phase 2a program for Treatment-Resistant Depression (TRD). This program builds on our co-founder John Krystal's work Yale University that showed that the combination may extend the antidepressant effects of ketamine from 2-7 days up to 2 to 3 weeks. https://lnkd.in/dGc-iTXd
-
We are honored to sponsor tomorrow's Yale-NAMI Conference on Neuroscience and Mental Health 2024. This event provides an opportunity for community members, patients and their families, and providers to come together and hear about new advances in the care for mental illness from Yale experts. Join for enlightening discussions and the recognition of Dr. Lawrence Hartmann with the Mental Health Advocacy Award. Yale University Yale School of Medicine NAMI Freedom Biosciences
Yale NAMI Conference on Neuroscience and Mental Health
medicine.yale.edu
-
Congratulations to John Krystal, Dennis S. Charney, MD and Husseini Manji, M.D., F.R.C.P.C., who were recipients of the prestigious National Academy of Medicine (NAM) Rhoda and Bernard Sarnat International Prize in Mental Health in Washington, D.C. last week. This award comes almost 25 years after the original discovery of ketamine as an antidepressant and 4.5 years after the FDA approval of SPRAVATO esketamine spray. At Freedom Bio we are especially proud of this achievement as our Co-founder John Krystal and Head of our SAB Rob Berman ran the first-ever study which demonstrated that ketamine was an antidepressant, and our CMO David Hough worked with Dr. Manji for 7 years at Janssen Inc. to lead the development of esketamine SPRAVATO. The team at Freedom Bio is now building on top of their legacies as we work to develop the next generation ketamine treatment. Over 300 million people are struggling with major depressive disorder globally, with 30% continuing to be treatment-resistant. Innovative mental health treatments, such as ketamine and esketamine, are imperative to help these patients. As Thomas Insel MD, former Director of National Institute of Mental Health (NIMH) said, "Recent data suggest that Ketamine, given intravenously, might be the most important breakthrough in antidepressant treatment in decades."
-